Gabriel Filipe Rodrigues Silva Barboza

Gabriel Filipe Rodrigues Silva Barboza

Auto-generated profile, based on publicly available information

Gabriel Filipe Rodrigues Silva Barboza

Medical student at Federal University of Viçosa (UFV) Viçosa, Minas Gerais, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2025 in Photochemistry and Photobiology
Verified
Journal Article
Open access
GBGabriel Barboza
Gabriel Barboza
JOJêmina Oliveira
Jêmina Oliveira
AFAntônio Ferreira
Antônio Ferreira
RLRenan Lopes
Renan Lopes
MCMarli do Carmo Cupertino
Marli do Carmo Cupertino
Light pollution from widespread artificial illumination affects photosensitive organisms, including humans. Prolonged exposure to artificial light at night (ALAN), particularly blue light, is associated with melatonin suppression and circadian disruption, both implicated in carcinogenesis. This systematic review investigated the relationship between extended ALAN exposure and malignant neoplasms, identifying associated cancer types and biological mechanisms. A search was conducted in PubMed/Medline and Scopus using PRISMA guidelines. Original studies evaluating associations between ALAN, light pollution, or blue light and cancer in humans were included. Eighteen studies demonstrated a positive link between ALAN and breast cancer, with mechanisms involving interference in the cell cycle, DNA repair, oxidative stress, and activation of oncogenic pathways. Night‐shift work correlated with increased breast cancer risk, reduced melatonin levels, and hormonal dysregulation. Exogenous melatonin showed oncostatic potential, reversing epigenetic changes induced by ALAN and reducing tumor burden. Melatonin suppression may promote tumor progression through circadian gene disruption and hormonal imbalance. While findings support a consistent link between ALAN exposure and oncogenesis—especially breast and prostate cancers—methodological variability and confounding factors, such as genetic predisposition and lifestyle, limit generalization. Further studies are needed to clarify mechanisms and explore preventive strategies, including light pollution control and melatonin‐based interventions.

4 November 2025 in Revista Brasileira de Neurologia
Verified
Journal Article
Open access
PDF file
TCTamires De Abreu Cosendey
Tamires De Abreu Cosendey
AFAna Laura Matoso da Fonseca
Ana Laura Matoso da Fonseca
GCGabriela Souza Carvalho
Gabriela Souza Carvalho
JDJosé Carlos Rodrigues Duarte
José Carlos Rodrigues Duarte
LRLyvia Mendes Ramos
Lyvia Mendes Ramos
MCMarli do Carmo Cupertino
Marli do Carmo Cupertino
The widespread availability of melatonin without a prescription, combined with the lack of specific medications for certain disorders with increasing morbidity rates, is significant factors driving the rise in melatonin use over the past decade. Despite its growing popularity, uncertainties surrounding optimal dosage and duration of exposure remain critical concerns, as these factors could increase the risk of overexposure and adverse effects. This study aims to update the therapeutic indications for melatonin, as well as assess its prescription, and therapeutic strategies. An updated search was conducted utilizing the descriptors (melatonin AND (children OR child OR adolescent)). Results presents melatonin's use for sleep disorders, autism spectrum disorder, neurodevelopmental disorders, and Attention Deficit/Hyperactivity Disorder, along with a smaller number of studies exploring its therapeutic potential in conditions such as atopic dermatitis, obesity, functional abdominal pain disorders, Bipolar Affective Disorder, neurogenetic syndromes, and Bourneville disease. Pediatric-appropriate prolonged-release melatonin in correct dosages has demonstrated positive results in clinical trials and appears to be the predominant formulation. The dosage adjustment phase is crucial for successful treatment. Significant variations in dosage, adaptation time, and exposure time were observed across clinical trials, complicating the comparison of results.